Announcements Trials
Browse Landscape

Phase

Phase 3 11Phase 2 5Phase 2/3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9Trastuzumab 8anlotinib 7Injections 7Rituximab 6venetoclax 5atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Azacitidine 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × masitinib × Clear all
NCT02490488 2020-12-08

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

AB Science

Phase 2/3 Completed
248 enrolled
Gynecologic

Ovarian Neoplasms

NCT03556956 2020-12-08

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

AB Science

Phase 2/3 Completed
219 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡